Clinical Trials Logo

Clinical Trial Summary

Cardiac amyloidosis is a disorder characterized by the deposition of abnormal proteins called amyloid in the heart tissue. This makes it difficult for the heart to function properly. The investigators wish to evaluate if the radiopharmaceutical 18F‑Florbetaben (Neuraceq®) that targets beta amyloid can also identify cardiac amyloid deposition.


Clinical Trial Description

The use of hybrid positron emission tomography/ magnetic resonance imaging (PET/MRI) scanners in clinical practice enhance the ability to evaluate the heart from both an anatomical and functional perspective. It is hypothesized that an increased PET signal of 18F‑Florbetaben (Neuraceq®) will be detected in cardiac amyloid deposits within the heart tissue, while the MRI provides the anatomical information. The ability to reliably and non-invasively image amyloid deposition in the heart would be potentially advantageous in the following scenarios:

1. Diagnosis of cardiac amyloidosis

2. Decreasing unnecessary invasive myocardial procedures.

The investigators believe this trial will help expand the use of current PET amyloid tracers and help many patients who currently undergo myocardial biopsy for the diagnosis of cardiac amyloid. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03119558
Study type Interventional
Source Stanford University
Contact
Status Completed
Phase Early Phase 1
Start date May 26, 2016
Completion date August 28, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT04459169 - Cardiac Amyloidosis : Diagnostic Using Red Flag Signals
Recruiting NCT03029026 - The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
Recruiting NCT06034405 - Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
Recruiting NCT04915235 - Prevalence and Prognosis of Cardiac Amiloidosis in Turkey
Recruiting NCT02966522 - Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis Phase 2
Terminated NCT03333551 - Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy Phase 4
Recruiting NCT04105634 - Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT Early Phase 1
Recruiting NCT05139797 - Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
Not yet recruiting NCT05593679 - A Multi-center Cardiac PYP Scan Registry in Taiwan.
Not yet recruiting NCT04146415 - Diagnosis of Cardiac Amyloidosis With 99mTc-PYP; Comparison Between Planar Imaging, SPECT/CT and Cardiac-dedicated CZT Camera N/A
Not yet recruiting NCT06427304 - Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure
Recruiting NCT06469372 - Cardiac Amyloidosis Discovery Trial N/A
Recruiting NCT04856267 - Exploration of Arrhythmia Burden in Cardiac Amyloidosis Using Implantable Loop Recorders
Recruiting NCT02798705 - Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis
Not yet recruiting NCT04387344 - Morpho-functional Cardiac Modifications in Treated Mutated Transthyretin Cardiac Amyloidosis
Recruiting NCT06129656 - Cardiac Amyloidosis Registry of University Hospital Leipzig
Terminated NCT01683825 - Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography Phase 4
Withdrawn NCT04363294 - Targeted Testing for ATTR Among Aortic Stenosis Patients-Pilot N/A
Not yet recruiting NCT04661800 - Study of Olfactory Disorders in Patients With Cardiac Amyloidosis N/A
Terminated NCT03232632 - Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries. Early Phase 1